P85 REAL WORLD EXPERIENCE ON THE USE OF SGLT2–I IN ELDERLY PATIENTS WITH HFREF

Abstract SGLT2–i have been shown to improve prognosis in patients with heart failure reduced ejection fraction (HFrEF) randomized clinical trials (RCTs). However, at the moment, we little data on use of these drugs practice, both terms safety and efficacy profile. Objectives To describe characteristics HFrEF outpatients who started practice; evaluate tolerability effect biohumoral parameters. Methods We prospectively analyzed our Heart Failure clinic. The baseline characteristics, variations bio–humoral parameters were recorded, as well onset adverse effects leading drug suspension after one month. Results evaluated 37 patients, a mean age 77.7± 8.5 years (65% over 75). population compared that treatment arms RCTs are Fig.1. Most NYHA II (62%), ischemic etiology (65%), EF (mean 34.7± 5.1%) nearly half received ICD or CRT–D (43.2%). At month follow–up, there was significant reduction class (Fig. 2)and furosemide dose (36.3 vs 53.2 mg, p<0.001), without change NTproBNP values ​​(2499 2431 pg /mL, p=0.804). Furthermore, systolic blood pressure (115 120 mmHg, p=0.029) no increase incidence orthostatic hypotension (27% 21%, p=0.48). In line trials, slight, non–significant worsening renal function (CKD–EPI 52.9 55.9 mL/min, p=0.10). month, experienced any discontinuation. Conclusions this preliminary analysis, therapy elderly hemodynamic improvement demonstrated by diuretic therapy. be relatively safe, increased risk function.